Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice

Title: Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice
Authors: Sandhu, G; Adattini, J; Armstrong Gordon, E; O'Neill, N; Bagnis, C; Boddy, AV; Chambers, P; Flynn, A; Hamilton, B; Ibrahim, K; Johnson, DW; Karapetis, C; Kelly, A; Kerr, KA; Kichenadasse, G; Kliman, DS; Kurkard, C; Liauw, W; Lucas, C; Mallett, AJ; Malyszko, J; McCaughan, G; Michael, M; Mirkov, S; Morris, E; Pollock, CA; Roberts, DM; Routledge, DJ; Scuderi, C; Shingleton, J; Shortt, J; Siderov, J; Sprangers, B; Stein, BN; Tey, A; Webber, K; Wichart, J; Wong, R; Ward, RL
Publisher Information: Elsevier
Publication Year: 2025
Collection: The University of Melbourne: Digital Repository
Description: Part 2 of the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) offers drug-specific consensus recommendations based on both evidence and practical experience. These recommendations build upon the kidney function assessment and classification guidelines established in Part 1 of ADDIKD. Here we illustrate how dosing recommendations differ between ADDIKD and existing guidance for four commonly used drugs: methotrexate, cisplatin, carboplatin and nivolumab. We then describe how the recommendations can be distilled into practice points for methotrexate and cisplatin. While ADDIKD is a significant improvement from previous guidelines, adoption of this new guideline requires further endorsement from key external stakeholders, ‘change championing’ by clinicians locally and encouraging its integration into existing reference sources, clinical trial protocols and electronic prescribing systems. Funding: Development of the ADDIKD guideline is funded by the NSW Government as part of the Cancer Institute NSW and received no funding from external commercial sources.
Document Type: article in journal/newspaper
Language: English
ISSN: 2589-5370
Relation: Sandhu, G., Adattini, J., Armstrong Gordon, E., O'Neill, N., Bagnis, C., Boddy, A. V., Chambers, P., Flynn, A., Hamilton, B., Ibrahim, K., Johnson, D. W., Karapetis, C., Kelly, A., Kerr, K. A., Kichenadasse, G., Kliman, D. S., Kurkard, C., Liauw, W., Lucas, C. ,. Ward, R. L. (2025). Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice. EClinicalMedicine, 82, https://doi.org/10.1016/j.eclinm.2025.103161.; https://hdl.handle.net/11343/360299
Availability: https://hdl.handle.net/11343/360299
Rights: https://creativecommons.org/licenses/by/4.0 ; CC BY
Accession Number: edsbas.81E6F6CF
Database: BASE